Drugs / 23-valent PPV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05477693 Comparator | Oct 2022 → Apr 2023 | pneumococcal infection | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 23-valent PPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05477693 ↗ |
| Modality | Vaccine | “The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.” NCT05477693 ↗ |